Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312173627> ?p ?o ?g. }
- W4312173627 abstract "In addition to complications of acute diseases, chronic viral infections are linked to both malignancies and autoimmune disorders. Lack of adequate treatment options for Epstein-Barr virus (EBV), Human T-lymphotropic virus type 1 (HTLV-1), and human papillomavirus (HPV) remains. The NexImmune Artificial Immune Modulation (AIM) nanoparticle platform can be used to direct T cell responses by mimicking the dendritic cell function. In one application, AIM nanoparticles are used ex vivo to enrich and expand (E+E) rare populations of multi-antigen-specific CD8+ T cells for use of these cells as an AIM adoptive cell therapy. This study has demonstrated using E+E CD8+ T cells, the functional relevance of targeting EBV, HTLV-1, and HPV. Expanded T cells consist primarily of effector memory, central memory, and self-renewing stem-like memory T cells directed at selected viral antigen peptides presented by the AIM nanoparticle. T cells expanded against either EBV- or HPV-antigens were highly polyfunctional and displayed substantial in vitro cytotoxic activity against cell lines expressing the respective antigens. Our initial work was in the context of exploring T cells expanded from healthy donors and restricted to human leukocyte antigen (HLA)-A*02:01 serotype. AIM Adoptive Cell Therapies (ACT) are also being developed for other HLA class I serotypes. AIM adoptive cell therapies of autologous or allogeneic T cells specific to antigens associated with acute myeloid leukemia and multiple myeloma are currently in the clinic. The utility and flexibility of the AIM nanoparticle platform will be expanded as we advance the second application, an AIM injectable off-the-shelf nanoparticle, which targets multiple antigen-specific T cell populations to either activate, tolerize, or destroy these targeted CD8+ T cells directly in vivo, leaving non-target cells alone. The AIM injectable platform offers the potential to develop new multi-antigen specific therapies for treating infectious diseases, cancer, and autoimmune diseases." @default.
- W4312173627 created "2023-01-04" @default.
- W4312173627 creator A5002656450 @default.
- W4312173627 creator A5005647147 @default.
- W4312173627 creator A5013746397 @default.
- W4312173627 creator A5014527241 @default.
- W4312173627 creator A5024667876 @default.
- W4312173627 creator A5031755873 @default.
- W4312173627 creator A5036560782 @default.
- W4312173627 creator A5041927134 @default.
- W4312173627 creator A5042633590 @default.
- W4312173627 creator A5051036578 @default.
- W4312173627 creator A5055075571 @default.
- W4312173627 creator A5081596205 @default.
- W4312173627 creator A5082413170 @default.
- W4312173627 date "2022-12-23" @default.
- W4312173627 modified "2023-10-01" @default.
- W4312173627 title "AIM™ platform: A new immunotherapy approach for viral diseases" @default.
- W4312173627 cites W1545785914 @default.
- W4312173627 cites W1580557214 @default.
- W4312173627 cites W1648161244 @default.
- W4312173627 cites W1831583280 @default.
- W4312173627 cites W1946675397 @default.
- W4312173627 cites W1966529586 @default.
- W4312173627 cites W1966646357 @default.
- W4312173627 cites W1977939808 @default.
- W4312173627 cites W1983062149 @default.
- W4312173627 cites W1985467654 @default.
- W4312173627 cites W1989273697 @default.
- W4312173627 cites W1989729492 @default.
- W4312173627 cites W2007354859 @default.
- W4312173627 cites W2015232856 @default.
- W4312173627 cites W2019068469 @default.
- W4312173627 cites W2019152707 @default.
- W4312173627 cites W2019164609 @default.
- W4312173627 cites W2022234493 @default.
- W4312173627 cites W2022316498 @default.
- W4312173627 cites W2022678076 @default.
- W4312173627 cites W2030099809 @default.
- W4312173627 cites W2034954827 @default.
- W4312173627 cites W2047192675 @default.
- W4312173627 cites W2077521424 @default.
- W4312173627 cites W2086601270 @default.
- W4312173627 cites W2093964518 @default.
- W4312173627 cites W2099736081 @default.
- W4312173627 cites W2102957457 @default.
- W4312173627 cites W2113030185 @default.
- W4312173627 cites W2115129006 @default.
- W4312173627 cites W2117674460 @default.
- W4312173627 cites W2119088702 @default.
- W4312173627 cites W2120020619 @default.
- W4312173627 cites W2123440147 @default.
- W4312173627 cites W2123823922 @default.
- W4312173627 cites W2130178313 @default.
- W4312173627 cites W2140481064 @default.
- W4312173627 cites W2144056674 @default.
- W4312173627 cites W2144796561 @default.
- W4312173627 cites W2145141007 @default.
- W4312173627 cites W2149745130 @default.
- W4312173627 cites W2158849175 @default.
- W4312173627 cites W2163646709 @default.
- W4312173627 cites W2166251447 @default.
- W4312173627 cites W2263755362 @default.
- W4312173627 cites W2264490770 @default.
- W4312173627 cites W2480418585 @default.
- W4312173627 cites W2568175915 @default.
- W4312173627 cites W2570323108 @default.
- W4312173627 cites W2619094261 @default.
- W4312173627 cites W2752025388 @default.
- W4312173627 cites W2803500691 @default.
- W4312173627 cites W2804779410 @default.
- W4312173627 cites W2908909305 @default.
- W4312173627 cites W3014954266 @default.
- W4312173627 cites W3043933877 @default.
- W4312173627 cites W3100123927 @default.
- W4312173627 cites W3156577277 @default.
- W4312173627 cites W3159637180 @default.
- W4312173627 cites W3208089728 @default.
- W4312173627 cites W3212443647 @default.
- W4312173627 cites W3216456568 @default.
- W4312173627 cites W4205314763 @default.
- W4312173627 cites W4238307265 @default.
- W4312173627 cites W4282966989 @default.
- W4312173627 doi "https://doi.org/10.3389/fmed.2022.1070529" @default.
- W4312173627 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36619639" @default.
- W4312173627 hasPublicationYear "2022" @default.
- W4312173627 type Work @default.
- W4312173627 citedByCount "0" @default.
- W4312173627 crossrefType "journal-article" @default.
- W4312173627 hasAuthorship W4312173627A5002656450 @default.
- W4312173627 hasAuthorship W4312173627A5005647147 @default.
- W4312173627 hasAuthorship W4312173627A5013746397 @default.
- W4312173627 hasAuthorship W4312173627A5014527241 @default.
- W4312173627 hasAuthorship W4312173627A5024667876 @default.
- W4312173627 hasAuthorship W4312173627A5031755873 @default.
- W4312173627 hasAuthorship W4312173627A5036560782 @default.
- W4312173627 hasAuthorship W4312173627A5041927134 @default.
- W4312173627 hasAuthorship W4312173627A5042633590 @default.
- W4312173627 hasAuthorship W4312173627A5051036578 @default.
- W4312173627 hasAuthorship W4312173627A5055075571 @default.